CellOrigin Biotech
赛元生物
CellOrigin Biotech
Biotech/Healthcare
Saiyuan Biotechnology (Hangzhou) develops and commercializes immune cells, such as macrophages and NK cells, differentiated from engineered pluripotent stem cells, including iPSCs and ESCs. The company owns proprietary intellectual property for what it describes as the world's first technology…
Latest round: Series C (2023)
Source: ChinaBulls — chinabulls.com
Last updated 2023-09-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.